WHY IT MATTERS: If state health authorities move forward with potency restrictions or new labeling requirements, patients who rely on higher-concentration products for legitimate medical purposes may face reduced access or need to significantly adjust their dosing strategies. CLINICAL OVERVIEW: Public health officials are raising concerns about the increasing potency of cannabis products available in the legal market, particularly regarding exposure among adolescents and young people. The discussion centers on how THC concentrations in modern products differ substantially from those in cannabis consumed decades ago, and what that means for developing brains.
Study: Teen Cannabis Use Linked to Double Psychosis Risk
This is one of the largest studies ever conducted on teen cannabis use and psychiatric outcomes, and it reinforces that age restrictions and youth prevention should be central to any legalization framework. A JAMA Health Forum study of 463,396 adolescents ages 13 to 17 found cannabis use was linked to a twofold increase in psychotic and bipolar disorder risk by age 26. The study represents one of the largest longitudinal investigations of this association, drawing on clinical health records rather than self-reported data.